Skip to content

Pharmacokinetics of Meropenem During High-dose CRRT

Pharmacokinetics of Meropenem During High-dose Continuous Renal Replacement Therapy in Critically Ill Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03507751
Enrollment
19
Registered
2018-04-25
Start date
2018-04-02
Completion date
2019-02-02
Last updated
2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Renal Failure

Brief summary

Assessment of meropenem plasma concentration in critically ill patients who require CRRT (continuous renal replacement therapy). A standard dose of meropenem is administered, i.e. 1 gram every 8 hours.

Detailed description

This is a prospective observational study performed on critically ill patients. Inclusion criteria are a severe infection on admission requiring the use of meropenem and CRRT. Both medical and surgical patients will be included. Any type of infections can be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes one-hour infusion of meropenem (1.0 gram) intravenously every 8 hours. Blood samples (2 mL) will be collected at the 15, 30, 45, 60, 75, 90, 120, 180, 240, and 480 minutes after each dose of meropenem for 3 consecutive days. The standard arterial canula will be used to obtain samples. 30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen. Serum meropenem concentration will be measured by high-performance liquid chromatography. Each patient's hemodynamic parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies, i.e. ventilatory support, sedation, an antifungal agent will be given as required.

Interventions

DRUGMeropenem

1.0 gram of meropenem given intravenously every 8 hours

DEVICECRRT

Continuous renal replacement therapy for three days

Sponsors

University of Warmia and Mazury in Olsztyn
CollaboratorOTHER
Medical University of Lublin
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who require ICU treatment due to severe infection * age 18-80 years * an eligible consent obtained from the patient or his/her attendant

Exclusion criteria

* allergy to meropenem * lack of consent to participate in the study * age of patients below 18 or above 80 years

Design outcomes

Primary

MeasureTime frame
Plasma concentration of meropenem3 days

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026